Table of Content

1. Introduction to Selective Estrogen Receptor Degraders (SERDs)
1.1 Overview
1.2 Evolution of SERDs


2. Selective Estrogen Receptor Degraders - Mechanism of Action


3. Selective Estrogen Receptor Inhibitors as Combinational Therapy
3.1 SERD with CDK 4/6 Inhibitors
3.2 SERD with PI3K Inhibitors
3.3 SERD with Aromatase Inhibitors
3.4 SERDs with mTOR Inhibitors


4. Role of SERDs in Cancer Treatment


5. Selective Estrogen Receptor Degraders in Breast Cancer
5.1 Impact of SERDs in Breast Cancer Treatment
5.2 Ongoing Research & Development
5.2.1 AZD 9833
5.2.2 Rintodestrant (G1T48)
5.2.3 ZN-c5
5.2.4 Elacestrant (RAD1901)
5.2.5 LSZ 102
5.2.6 OP-1250
5.2.7 LY3484356
5.2.8 GDC-9545 (RG6171)
5.2.9 SHR9549
5.2.10 AZD9496



6. Selective Estrogen Receptor Degrader Market Analysis
6.1 Current Market Scenario
6.2 Impact of COVID-19 on Selective Estrogen Receptor Degrader Market
6.3 Market Opportunity


7. Selective Estrogen Receptor Degrader - Market Trends
7.1 Zentalis Pharma Collaborated with Eli Lily to Evaluate the Combination of SERD
with CDK4/6 Inhibitors
7.2 Olema Oncology & Novartis Announces Clinical Collaboration to Evaluate SERD
as Combinational Therapy
7.3 New SERD Combinational Therapy Shows Promising Results against HR+/HER2
Negative Breast Cancer
7.4 Radius & Menarini Collaborates for Development & Commercialization of
Elacestrant
7.5 SERD Combination Can Target the Neurofibromatosis Gene for Treating Breast
Cancer


8. Selective Estrogen Receptor Degrader (SERD) Inhibitors Clinical Trials Overview
8.1 By Company
8.2 By Indication
8.3 By Patient Segment
8.4 By Phase


9. Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight
9.1 Preclinical
9.2 Phase-I
9.3 Phase-I/II
9.4 Phase-II
9.5 Phase-III



10. Marketed Selective Estrogen Receptor Degrader (SERD) Insight: Fulvestrant


11. Faslodex (Fulvastrant)- Commercially Available Selective Estrogen Receptor Inhibitor Drug
11.1 Approval & Patent Dispute
11.2 Pricing & Dosage Analysis
11.3 Sales Analysis
11.4 Faslodex - Reimbursement Scenario


12. Generic Fulvestrant - Availability & Price Analysis
12.1 Fulviglen
12.2 Fulvenat
12.3 Fulvetraz
12.4 Fuvesterol
12.5 Strantas
12.6 Celvestrant
12.7 Faslomax
12.8 Fasnorm


13. Competitive Landscape
13.1 AsteraZeneca
13.2 Eli Lilly
13.3 G1 Therapeutics
13.4 Novartis
13.5 Olema Oncology
13.6 Radius Therapeutics
13.7 Roche
13.8 Sage Therapeutics
13.9 Zeno Pharma
13.10 Zentalis



List of Figures


Figure 1-1: Evolution of SERDs Drugs

Figure 2-1: Role of Estrogen Receptor in Tumor Development
Figure 2-2: Mechanism of Selective Estrogen Receptor Degraders
Figure 2-3: Mechanism of SERDs in Combination with other Cancer Therapeutics

Figure 3-1: CDK 4/6 Inhibitors Used in Combination with SERDs
Figure 3-2: PI3K Inhibitors Used in Combination with SERDs
Figure 3-3: Aromatase Inhibitors Used in Combination with SERDs

Figure 4-1: Global – Breast Cancer Cases by Nature of Estrogen Receptor (%), 2020
Figure 4-2: Role of SERDs in Cancer Management

Figure 5-1: Global – Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
Figure 5-2: Global – Breast Cancer Cases by Type (Million), 2020
Figure 5-3: Investigational SERDs Candidates & Their Manufacturers
Figure 5-4: SERENA-2 Trial – Study Initiation & Expected Completion Year For Primary Breast Cancer
Figure 5-5: SERENA-2 Trial – Study Initiation & Expected Completion Year for Advanced Breast Cancer
Figure 5-6: SERENA-1 Trial – Study Initiation & Expected Completion Year
Figure 5-7: AZD9833 Japan Trial – Study Initiation & Expected Completion Year
Figure 5-8: Rintodestrant Phase I Trial – Study Initiation & Expected Completion Year
Figure 5-9: ZN-c5 Monotherapy Trial – Study Initiation & Expected Completion Year
Figure 5-10: ZN-c5/Abemaciclib Combination Trial– Study Initiation & Expected Completion Year
Figure 5-11: ZN-c5/ Palbociclib Trial– Study Initiation & Expected Completion Year
Figure 5-12: Elacestrant Phase 3 Trial– Study Initiation & Expected Completion Year
Figure 5-13: Elacestrant – Study Initiation & Completion Year
Figure 5-14: LSZ102 Phase I/II Trial– Study Initiation & Completion Year
Figure 5-15: OP-1250 Phase I/II Trial – Study Initiation & Completion Year
Figure 5-16: EMBER-2 Trial – Study Initiation & Expected Completion Year
Figure 5-17: LY3484356 Phase I Trial – Study Initiation & Expected Completion Year
Figure 5-18: GDC-9545 Phase I Trial– Study Initiation & Expected Completion Year
Figure 5-19: GDC-9545/Fulvestrant Combinational Trial – Study Initiation & Expected Completion Year
Figure 5-20: SHR 9549 Phase I Trial – Study Initiation & Completion Year

Figure 6-1: Global – SERD Market Size (US$ Million), 2016 - 2020
Figure 6-2: Global – SERD Market Size by Type of Product (US$ Million), 2019
Figure 6-3: Global – SERD Market Size by Type of Product (%), 2019
Figure 6-4: Global – Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity, 2020
Figure 6-5: Global – Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity (%), 2020
Figure 6-6: Global – Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
Figure 6-7: Global – Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
Figure 6-8: Global – Estimated ER Positive Breast Cancer Cases (Million), 2020, 2025 & 2030
Figure 6-9: Global – SERD Market Opportunity (US$ Billion), 2020 - 2025
Figure 6-10: US – SERD Market Opportunity (US$ Million), 2020 - 2025
Figure 6-11: Europe – SERD Market Opportunity (US$ Million), 2020 - 2025

Figure 8-1: SERD - Clinical Trials by Company (Number of Drugs), 2020 - 2025
Figure 8-2: SERD - Clinical Trials by Indication (Number of Drugs), 2020 - 2025
Figure 8-3: SERD - Clinical Trials by Patient Segment (Number of Drugs), 2020 - 2025
Figure 8-4: SERD - Clinical Trials by Phase (Number of Drugs), 2020 - 2025

Figure 11-1: Faslodex – FDA Approval Year by Type of Breast Cancer
Figure 11-2: Faslodex – FDA Approval Year & First Generic Approval Year
Figure 11-3: Faslodex - Patent Issue & Expiration Year
Figure 11-4: Faslodex – Price for 10 ml & Price per ml of Intramuscular Injection (US$), January’2021
Figure 11-5: Faslodex – Recommended & Reduced Dose (mg)
Figure 11-6: Faslodex – Number of Doses by Treatment Phase
Figure 11-7: Faslodex – Cost For First & Subsequent Treatment Cycle (US$)
Figure 11-8: Global - Faslodex Annual Sales Value (US$ Million), 2016 - 2019
Figure 11-9: Global - Faslodex Annual Sales Values (US$ Million), 2002 - 2015
Figure 11-10: Global - Faslodex Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 11-11: US - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
Figure 11-12: Europe - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
Figure 11-13: Global - Faslodex Annual Sales Value by Region (US$ Million), 2019
Figure 11-14: Global - Faslodex Annual Sales Value by Region (%), 2019
Figure 11-15: Global - Faslodex Quarterly Sales Value (US$ Million), Q1 – Q3, 2020
Figure 11-16: Global - Faslodex 9 Month Sales Value by Region (US$ Million), 2020
Figure 11-17: Global - Faslodex 9 Month Sales Value by Region (%), 2019
Figure 11-18: US - Faslodex Quarterly Sales Value (US$ Million), Q1 – Q3, 2020
Figure 11-19: Europe - Faslodex Quarterly Sales Value (US$ Million), Q1 – Q3, 2020
Figure 11-20: US – Typical Co-Pay Range of Branded & Generic Fulvestrant (US$), January’2021

Figure 12-1: Fulviglen – Price for a Supply of 3 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-2: Fulviglen – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-3: Fulviglen – Price for a Supply of 9 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-4: Fulvenat – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-5: Fulvenat – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-6: Fulvenat – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-7: Fulvetraz – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-8: Fulvetraz – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-9: Fulvetraz – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-10: Fuvesterol – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-11: Fuvesterol – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-12: Fuvesterol – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-13: Strantas – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-14: Strantas – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-15: Strantas – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-16: Celvestrant – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-17: Celvestrant – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-18: Celvestrant – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-19: Faslomax – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-20: Faslomax – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-21: Faslomax – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-22: Fasnorm – Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-23: Fasnorm – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021
Figure 12-24: Fasnorm – Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January’2021